当前位置: 首页 >> 检索结果
2042. Prognostic Value of Echocardiographic Variables Prior to and Following Initiation of Parenteral Prostacyclin Therapy: An Observational Study.
作者: Trushil Shah.;Pratyusha Manthena.;Chandni Patel.;Ashleigh Chuah.;E Ashley Hardin.;Fernando Torres.;Sonja D Bartolome.;Kelly M Chin.
来源: Chest. 2022年162卷3期669-683页
Echocardiographic parameters are used as prognostic markers in patients with pulmonary arterial hypertension (PAH) receiving parenteral (IV or subcutaneous [IV/SC]) prostacyclin therapy. However, data on how posttreatment echocardiographic results associate with outcomes are limited.
2043. The Association of Health Care System Resources With Lung Cancer Screening Implementation: A Cohort Study.
作者: Jennifer A Lewis.;Lauren R Samuels.;Jason Denton.;Michael E Matheny.;Amelia Maiga.;Christopher G Slatore.;Eric Grogan.;Jane Kim.;Robert H Sherrier.;Robert S Dittus.;Pierre P Massion.;Laura Keohane.;Christianne L Roumie.;Sayeh Nikpay.
来源: Chest. 2022年162卷3期701-711页
The Veterans Health Administration issued policy for lung cancer screening resources at eight Veterans Affairs Medical Centers (VAMCs) in a demonstration project (DP) from 2013 through 2015.
2044. Defibrotide Therapy for SARS-CoV-2 ARDS.
作者: David Frame.;Gianni B Scappaticci.;Thomas M Braun.;Mary Maliarik.;Thomas H Sisson.;Steven W Pipe.;Daniel A Lawrence.;Paul G Richardson.;Michael Holinstat.;Robert C Hyzy.;Daniel R Kaul.;Kevin S Gregg.;Vibha N Lama.;Gregory A Yanik.
来源: Chest. 2022年162卷2期346-355页
SARS-CoV-2-related ARDS is associated with endothelial dysfunction and profound dysregulation of the thrombotic-fibrinolytic pathway. Defibrotide is a polyanionic compound with fibrinolytic, antithrombotic, and antiinflammatory properties.
2045. Optimizing COPD Acute Care Patient Outcomes Using a Standardized Transition Bundle and Care Coordinator: A Randomized Clinical Trial.
作者: Chantal E Atwood.;Mohit Bhutani.;Maria B Ospina.;Brian H Rowe.;Richard Leigh.;Lesly Deuchar.;Peter Faris.;Marta Michas.;Kelly J Mrklas.;Jim Graham.;Raymond Aceron.;Ron Damant.;Lee Green.;Naushad Hirani.;Kelly Longard.;Virginia Meyer.;Patrick Mitchell.;Willis Tsai.;Brandie Walker.;Michael K Stickland.
来源: Chest. 2022年162卷2期321-330页
Acute exacerbations of COPD (AECOPD) are associated with high morbidity and mortality and frequent readmissions.
2046. Racial Disparities in the Surgical Treatment of Clinical Stage I Non-Small Cell Lung Cancer Among Veterans.
作者: Brendan T Heiden.;Daniel B Eaton.;Su-Hsin Chang.;Yan Yan.;Ana A Baumann.;Martin W Schoen.;Mayank R Patel.;Daniel Kreisel.;Ruben G Nava.;Bryan F Meyers.;Benjamin D Kozower.;Varun Puri.
来源: Chest. 2022年162卷4期920-929页
Prior studies in the civilian population have reported racial disparities in lung cancer outcomes following surgical treatment, including inferior quality of care and worse survival. It is unclear if racial disparities exist in the Veterans Health Administration (VHA), the largest integrated health care system in the United States.
2047. Predicting Usual Interstitial Pneumonia Histopathology From Chest CT Imaging With Deep Learning.
作者: Alex Bratt.;James M Williams.;Grace Liu.;Ananya Panda.;Parth P Patel.;Lara Walkoff.;Anne-Marie G Sykes.;Yasmeen K Tandon.;Christopher J Francois.;Daniel J Blezek.;Nicholas B Larson.;Bradley J Erickson.;Eunhee S Yi.;Teng Moua.;Chi Wan Koo.
来源: Chest. 2022年162卷4期815-823页
Idiopathic pulmonary fibrosis (IPF) is a progressive, often fatal form of interstitial lung disease (ILD) characterized by the absence of a known cause and usual interstitial pneumonitis (UIP) pattern on chest CT imaging and/or histopathology. Distinguishing UIP/IPF from other ILD subtypes is essential given different treatments and prognosis. Lung biopsy is necessary when noninvasive data are insufficient to render a confident diagnosis.
2048. MUC5B Promoter Polymorphism and Survival in Indian Patients With Idiopathic Pulmonary Fibrosis.
作者: Sahajal Dhooria.;Amanjit Bal.;Inderpaul Singh Sehgal.;Kuruswamy Thurai Prasad.;Dharambir Kashyap.;Riya Sharma.;Valliappan Muthu.;Ritesh Agarwal.;Ashutosh Nath Aggarwal.
来源: Chest. 2022年162卷4期824-827页 2049. Impact of Esophageal Pressure Measurement on Pulmonary Hypertension Diagnosis in Patients With Obesity.
作者: Ghaleb Khirfan.;Celia A Melillo.;Sami Al Abdi.;James E Lane.;Raed A Dweik.;Robert L Chatburn.;Umur Hatipoğlu.;Adriano R Tonelli.
来源: Chest. 2022年162卷3期684-692页
Elevated intrathoracic pressure could affect pulmonary vascular pressure measurements and influence pulmonary hypertension (PH) diagnosis and classification. Esophageal pressure (Pes) measurement adjusts for the increase in intrathoracic pressure, better reflecting the pulmonary hemodynamics in patients with obesity.
2050. No VTE Recurrence After 1-Year Follow-Up of Hospitalized Patients With COVID-19 and a VTE Event: A Prospective Study.
作者: Maxime Delrue.;Alain Stépanian.;Sebastian Voicu.;Kladoum Nassarmadji.;Damien Sène.;Philippe Bonnin.;Jean-Philippe Kevorkian.;Pierre-Olivier Sellier.;Jean-Michel Molina.;Marie Neuwirth.;Dominique Vodovar.;Stéphane Mouly.;Alexandre Mebazaa.;Bruno Mégarbane.;Virginie Siguret.
来源: Chest. 2022年162卷1期226-229页 2060. A 20-Year-Old Woman With Thoracic Pain and Progressive Dyspnea on Exertion.
作者: Eline G M Steenhuis.;Maaike M Brus.;Nils A 't Hart.;Liudmila L Kodach.;Jacqueline Nijboer-Oosterveld.;Benjamin Tomlow.
来源: Chest. 2022年161卷4期e233-e240页
A 20-year-old woman presented with dry cough, right-sided thoracic pain, and gradually progressive dyspnea on exertion. She had no hemoptysis or fever. There was no relevant medical history. She was a never smoker and used no medication besides oral contraceptives. There were no other risk factors for a pulmonary embolism. There was a family history of ovarian and breast cancer. Physical examination showed a mildly ill-looking woman, with shallow breathing and normal blood oxygen saturation. Auscultation revealed normal breath sounds without crackles or wheezing. Laboratory testing showed a significantly increased D-dimer (4,560 μg/L [normal, < 500 μg/L]), elevated C-reactive protein (131 mg/L [normal, < 5 mg/L]), normal leucocytes, and elevated lactate dehydrogenase (825 units/L [normal, 50 to 250 units/L).
|